Haisco Pharmaceutical Group Co. Ltd. has described lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis, systemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback